Skip to main content
TipRanks
Go Ultimate75% OFF

Fate Therapeutics (FATE) AI Stock Analysis

1,295 Followers
FATE

Fate Therapeutics

(NASDAQ:FATE)

Select Model
Rating:42Neutral
Price Target:$0.98▼(-3.07% Downside)
Action:reiterated
Date:11/13/26

The score is held down primarily by weak financial performance (ongoing large losses, meaningful cash burn, and a shrinking equity cushion) and a clearly bearish technical setup (price below major moving averages with negative momentum). A positive offset comes from the $15M CIRM grant and related regulatory momentum, but valuation support is limited given negative earnings and no dividend.

Positive Factors
Clinical funding and regulatory momentumThe $15 million grant provides non-dilutive support for a potentially registrational trial and represents external validation of FT819. RMAT designation and FDA CMC pilot participation may also improve regulatory execution and strengthen the program’s development position.
Negative Factors
Small and declining revenue baseRevenue remains very small and is shrinking, while the company has no established recurring product sales from approved therapies. This leaves Fate dependent on collaboration-related income and future milestones rather than a diversified commercial revenue base.

Fate Therapeutics (FATE) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%FATE-6.48%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$122.39M
Dividend Yield
―
Average Volume (3M)
1.50M
Price to Earnings (P/E)
-1.0
Beta (1Y)
2.64
Revenue Growth
-33.45%
EPS Growth
21.90%
Country
US
Employees
161
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Fate Therapeutics Business Overview & Revenue Model

Company Description

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A signifi...

How the Company Makes Money

Fate Therapeutics does not have publicly established, recurring product sales from approved therapies; as a clinical-stage company, its revenue has primarily been generated from collaboration and licensing arrangements rather than commercial product...

Fate Therapeutics Earnings Call Summary

Earnings Call Date:May 09, 2024(Q1-2024)|% Change Since:-74.10%|Next Earnings Date:Mar 01, 2027
Earnings Call SentimentNeutral

The earnings call highlighted significant progress in clinical trials, particularly with FT819 and FT522, alongside a strong financial position. However, revenue growth remains limited and operating expenses are high, suggesting a balanced outlook with promising clinical achievements countered by financial challenges.

Positive Updates

FT819 and FT522 Data Presentation
Presented promising data from FT819 and FT522 programs at the ASGCT Annual Meeting, showing potential disease-modifying effects and immune reset in B-cell-mediated autoimmune diseases.

Negative Updates

Limited Revenue Growth
Reported revenue of $1.9 million, consistent with prior quarters, reflecting limited growth.

Company Guidance

During the Fate Therapeutics Q1 2024 earnings call, the company provided guidance on its clinical and financial outlook. Key program initiatives were discussed, including the FT819 CAR T-cell and FT522 CAR NK cell programs, with notable translational data presented at the American Society of Gene and Cell Therapy Annual Meeting. The company highlighted its plans to achieve several clinical milestones across its iPSC product pipeline, targeting both cancer and autoimmune diseases. Financially, Fate Therapeutics raised $100 million through an underwritten offering and private placement, ending the first quarter with approximately $391 million in cash. Operating expenses for the full year are projected between $215 million and $230 million, with a year-end cash balance exceeding $270 million. The company's strategic focus is on demonstrating the disease-modifying potential of its therapies while maintaining a strong financial position to support ongoing and future clinical development.

Fate Therapeutics Financial Statement Overview

Summary

Financials remain weak: very small and declining TTM revenue (~$4.8M, down ~27%), large ongoing net losses (~$124M), and substantial cash burn (TTM FCF about -$107M). While losses and burn have improved versus prior years and leverage is not extreme, the continued dependence on external funding and a shrinking equity base materially increase risk.

Income Statement

18Very Negative

Balance Sheet

46Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.75M6.65M13.63M63.53M96.30M55.85M
Gross Profit-846.00K-6.25M-104.90M-93.65M82.54M50.00M
EBITDA-114.95M-127.02M-176.58M-142.65M-267.96M-206.30M
Net Income-124.43M-136.31M-186.26M-160.93M-281.72M-212.15M
Balance Sheet
Total Assets238.28M318.94M440.69M506.22M705.56M921.46M
Cash, Cash Equivalents and Short-Term Investments139.13M203.66M279.07M315.18M436.23M615.91M
Total Debt74.49M77.85M85.27M103.54M109.34M114.82M
Total Liabilities105.24M111.75M121.97M137.80M221.62M242.62M
Stockholders Equity133.03M207.18M318.73M368.42M483.94M678.84M
Cash Flow
Free Cash Flow-106.97M-112.04M-123.60M-138.42M-283.77M-213.57M
Operating Cash Flow-105.46M-106.08M-122.87M-132.26M-248.21M-162.87M
Investing Cash Flow92.61M111.17M12.22M112.67M166.75M-324.02M
Financing Cash Flow11.05M5.49M99.89M85.00K9.21M453.13M

Fate Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price1.01

Price Trends

50DMA2.07Negative
100DMA2.35Negative
200DMA1.98Negative

Market Momentum

MACD-0.27Positive
RSI20.91Positive
STOCH2.52Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FATE, the sentiment is Negative. The current price of 1.01 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 2.07, and below the 200-day MA of 1.98, indicating a bearish trend. The MACD of -0.27 indicates Positive momentum. The RSI at 20.91 is Positive, neither overbought nor oversold. The STOCH value of 2.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FATE.

Fate Therapeutics Risk Analysis

Fate Therapeutics disclosed 90 risk factors in its most recent earnings report. Fate Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Off-label use or misuse of any product candidates we may get approved in the future may harm our reputation in the marketplace or result in injuries that lead to costly product liability suits.Q3, 2026
2.required for the conduct of our clinical trials and the manufacture of our product candidates and do not have supply arrangements for certain of these components.Q3, 2026
3.Off-label use or misuse of any product candidates we may get approved in the future may harm our reputation in the marketplace or result in injuries that lead to costly product liability suits.Q2, 2026

Fate Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FATE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CGENCGEN73Outperform$178.09M4.8339.30%―999.97%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ONCYONCY47Neutral$53.18M-1.38664.95%――11.90%
CRDFCRDF43Neutral$69.44M-1.62-111.78%―11.58%32.14%
NKTXNKTX43Neutral$80.31M-0.65-48.58%――-24.79%
STTKSTTK42Neutral$463.38M-8.92-46.46%―-100.00%50.26%
FATEFATE42Neutral$122.78M-0.98-73.92%―-33.45%21.90%

* Healthcare Sector Average

Performance Comparison

0%100%200%FATECGENONCYCRDFNKTXSTTKDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FATE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FATEFate Therapeutics Inc1.01-0.02-1.94%
CGENCompugen1.880.3522.88%
ONCYOncolytics Biotech0.39-0.61-61.00%
CRDFCardiff Oncology, Inc.0.89-1.14-56.06%
NKTXNkarta, Inc.1.12-0.68-37.78%
STTKShattuck Labs, Inc.4.552.52124.14%

Fate Therapeutics Corporate Events

Private Placements and Financing

Fate Therapeutics Enters $100 Million At-the-Market Sales Agreement

Neutral
Nov 5, 2026

On November 5, 2026, Fate Therapeutics entered a sales agreement with Leerink Partners for an at-the-market program allowing it, at its discretion, to sell up to $100 million of common stock. The agreement provides for commissions of up to 3% of gros...

Business Operations and StrategyPrivate Placements and Financing

Fate Therapeutics Secures CIRM Grant for FT819 Lupus Trial

Positive
Sep 28, 2026

On September 25, 2026, Fate Therapeutics announced that the California Institute for Regenerative Medicine awarded the company a $15 million CLIN2 grant to support RECLAIM-LN, its Phase 2 potentially registrational trial of FT819 in patients with ref...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026